You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm reported $6.3 million in third quarter revenues compared to $2.2 million in the year ago period, but fell short of the consensus Wall Street estimate of $7.5 million.
The technologies will be added to ClearLight's portfolio for the three-dimensional interrogation and imaging of tissue samples.
Abbott said that a lawsuit it filed Thursday tries to obtain important information from Alere before its acquisition is completed.
Esoterix sued Myriad in September, claiming that its myRisk Hereditary Cancer panel and services directly infringe four patents it has exclusively licensed.
Encouraged by positive customer feedback from early installations, the firm is shifting its sales focus to the ePlex system and respiratory pathogen panel.
The revenue increase was driven by increased sales of its Afirma gene classifier thyroid test, as well as improved predictability of payments.
The company added three genes to its panel and said it has improved its detection limits, although validation data for these new performance numbers is not yet published.
The kit is a qualitative nucleic acid assay designed to test for Zika, dengue, and chikungunya viruses simultaneously.
The firm said it is on track for solid future growth based on the expectation for new product approvals and continued strength in the CareFusion product portfolio.
Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.
The company beat analysts' consensus estimates on both the top and bottom lines as its molecular diagnostics sales rose 9 percent at constant exchange rates.
The company reported $29.4 million in revenues for the quarter and a net loss of $31.3 million, while the number of clinical tests increased to 11,627.
Despite lower than expected NGS instrument sales, Illumina expects continued growth in the oncology market as reimbursement increases.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The company said it would use the net proceeds from the offering for working capital, and possibly to acquire or invest in other companies or technologies.
The firm brought in total revenues of $177.5 million in the first quarter, compared to $183.5 million in Q1 2016, beating the consensus Wall Street estimate.
T2 and Allergan will develop a novel diagnostic panel for the detection of Gram-negative bacterial species and antibiotic resistance in patients with bacterial infections.
The firm said that it delivered more than 29,990 test results in the third quarter of 2016 compared to 27,820 results delivered in Q3 2015.
The firm reported revenues of $508.7 million, thanks largely to an 18 percent increase in sales from the company's life science segment.
The test is based on MDNA's Mitomic technology, which enables the isolation of mitochondrial DNA in circulation that may be used as biomarkers.